



Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes

Jelle Vehof^{a, b}, Huibert Burger^{a, b}, Bob Wilffert^c, Asmar Al Hadithy^{c, d}, Behrooz Z. Alizadeh^b, Harold Snieder^b
GROUP investigators^{*, 1}

^a Department of Psychiatry University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

^b Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

^c Department of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands

^d Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands

Received 6 September 2011; received in revised form 12 December 2011; accepted 17 January 2012

KEYWORDS

Antipsychotics;
Response;
Schizophrenia;
Polymorphism;
Pharmacogenetics;
Dopamine;
Serotonin

Abstract

Pharmacogenetic studies have demonstrated significant associations between several candidate genes (DRD2, DRD3, 5HTR2A and 5HTR2C, COMT and MTHFR) and antipsychotic drug response. The present study investigates the effect of nine polymorphisms in these genes for an association with antipsychotic treatment response. 329 Caucasian patients with a non-affective psychotic disorder using antipsychotics were included. All patients participated in the longitudinal GROUP-study in The Netherlands. We genotyped 9 SNPs in 6 candidate genes (DRD2: TaqI_A, -141C; DRD3: Ser9Gly; HTR2A: 102-T/C, His452Tyr; HTR2C: Cys23Ser; COMT: Val158Met;

* Correspondence to: Richard Bruggeman, Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

E-mail address: j.vehof@umcg.nl (J. Vehof).

¹ René S. Kahn, MD, PhD, Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands; Don H. Linszen, MD, PhD, Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Jim van Os, MD, PhD, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University Medical Centre, Maastricht, The Netherlands, and King's College London, King's Health Partners, Department of Psychosis Studies, Institute of Psychiatry, London, England, United Kingdom; Durk Wiersma, PhD, Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Richard Bruggeman, MD, PhD, Department of Psychiatry, University Medical Center Groningen, University of Groningen, The Netherlands; Wiepke Cahn, MD, PhD, Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, The Netherlands; Lieuwe de Haan, MD, PhD, Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands; Lydia Krabbendam, PhD, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University Medical Centre, The Netherlands; and Inez Myin-Germeys, PhD, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University Medical Centre, The Netherlands.

MTHFR: 677-C/T) using standard protocols. Polymorphisms were based on previous studies showing associations with positive symptoms treatment response. The Clinical Global Impression - Improvement (CGI-I) scale was used to assess improvement in positive psychotic symptoms since the start of current antipsychotic treatment. Ordinal regression was used for association analyses. Ninety percent of the patients used second generation antipsychotics, with olanzapine (28%) and risperidone (29%) being the most prescribed drugs. Ser9Gly of the dopamine D3 receptor gene (P value 0.034) and 677-C/T of MTHFR (P value 0.019) were tested statistically significant. Gly-carriers and T-carriers, respectively, showed more clinical improvement on the CGI-I. The other polymorphisms did not show a statistically significant association (P values > 0.10). In conclusion, we replicated two out of nine of the previously reported associations between polymorphisms and treatment response. The direction and magnitude of the associations presented here in DRD3 (Ser9Gly) and MTHFR (677-C/T) are in line with previous association studies in Caucasian patients. These polymorphisms may be of value for predicting clinical response.

© 2012 Elsevier B.V. and ECNP. All rights reserved.

1. Introduction

Since their introduction in the 1950s antipsychotic drugs play a key role in the treatment of psychotic disorders. However, almost half of patients with schizophrenia display insufficient response to antipsychotic treatment and many patients show low compliance as a result (Lacro et al., 2002). In turn, this may cause clinical deterioration including psychotic relapse. Factors that influence the variation in response to antipsychotic drug treatment have not been well elucidated. Inter-individual and inter-racial variability in response to drug treatment may possibly reflect genetic heterogeneity and the presence of modifier genes (Tsuang et al., 1990). Several genetic association studies have been performed showing positive associations between response and polymorphisms in genes coding for the dopaminergic, serotonergic, and several other systems. In this study we focus on polymorphisms associated with antipsychotic drug response (positive or global symptoms) in Caucasian patients only.

Dopamine D2 receptor blockade is a property of all antipsychotics. The polymorphisms Taq1A, located downstream of the dopamine receptor D2 gene (*DRD2*), and -141C Ins/Del, located in the promoter region of *DRD2*, are linked to D2 receptor density at the level of the striatum (Jonsson et al., 1999; Laakso et al., 2005; Pohjalainen et al., 1998). Several studies have associated Taq1A and -141C with response to first (FGA) and second generation antipsychotics (SGA) (Hwang et al., 2005; Lencz et al., 2006; Schafer et al., 2001). The affinity of certain antipsychotics for the D3 receptor may reflect a part of their action, although affinity for the D3 receptor may differ among them (Schwartz et al., 2000). The Ser9Gly polymorphism of *DRD3* is an amino-acid substitution in the N-terminal extracellular part of the receptor and might influence the membrane expression of this receptor by modifying its intracellular maturation (Reynolds et al., 2005). A positive relation between response to SGA and the presence of the Gly allele was found in three studies (Staddon et al., 2002; Szekeres et al., 2004; Scharfetter et al., 1999).

Alterations in the serotonergic system have been implicated in the mechanisms of action of antipsychotics, having antagonistic properties (particularly SGA) on serotonergic receptors, especially the serotonin 2A and 2C receptors. Two SNPs (His452Tyr and 102-T/C) of the *5HTR2A* (serotonin receptor 2A) gene were the subject of several association studies on the response to clozapine. Results were conflicting (Masellis

et al., 1995, 1998; Malhotra et al., 1996; Joobar et al., 1999; Jonsson et al., 1996; Arranz et al., 1995, 1996, 1998a, 1998b). The 102-T/C SNP does not entail amino acid substitution, but in Caucasian patients it is in complete linkage disequilibrium with variant -1438A/G, which is located in the gene promoter. The A allele of this polymorphism would increase the in-vitro activity of the promoter (Parsons et al., 2004). The His452Tyr polymorphism brings about functional modifications of the receptor, the Tyr variant would decrease the receptor's ability to activate C and D phospholipases (Hazelwood and Sanders-Bush, 2004). The serotonin 2C receptor is suggested to play a moderate role in the effect of antipsychotics on particularly negative symptoms (Sodhi et al., 1995; Reynolds et al., 2005; Arranz et al., 2000a; Lieberman et al., 1998). The Cys23Ser polymorphism of the *5HTR2C* (serotonin receptor 2C) gene was associated in one study with global response on clozapine (Sodhi et al., 1995). The consequences of the involved amino acid substitution are unknown.

COMT (catechol-O-methyltransferase) is involved in the degradation of dopamine in the prefrontal cortex. The *COMT* gene has a relevant Val158Met polymorphism (sometimes referred to as Val158/108Met). The Met allele was associated with a better response in two studies (Anttila et al., 2004; Bertolino et al., 2004). The MTHFR (methylenetetrahydrofolate reductase) enzyme is required for the synthesis of 5-MTHF, a cosubstrate for the conversion of homocysteine into methionine. Elevated plasma homocysteine concentration has been suggested as a risk factor for schizophrenia but the causality is still unclear. The *MTHFR* gene has a missense mutation 677-C/T. Patients possessing a copy of the T allele showed a better treatment response (Joobar et al., 2000a).

In the present study we tested above mentioned nine polymorphisms for their association with response on positive symptoms in a sample of Caucasian patients with a psychotic disorder. We focused on polymorphisms associated with response on positive symptoms because antipsychotics are mainly effective for treating positive symptoms.

2. Experimental procedures

2.1. Sample

A sample of 329 in- and outpatients using antipsychotic medication was drawn from the participants in the ongoing longitudinal Genetic Risk and Outcome of Psychosis (GROUP) study. In GROUP, patients

were identified in selected representative geographical areas in the Netherlands and Belgium. Inclusion criteria for GROUP were: (i) age range 16 to 50 years, (ii) DSM-IV diagnosis of non-affective psychotic disorder and (iii) good command of Dutch language. For the present analysis the following extra inclusion criteria were applied: (iv) use of antipsychotic medication at the time of assessment for at least one month and (v) Caucasian ethnicity of Northern European ancestry. The study was approved by the Ethics Committee of the University Medical Center Utrecht and by the institutional review boards of all other participating hospitals. All subjects gave written informed consent in accordance with the committee's guidelines.

2.2. Genotyping

A total of 9 polymorphisms in 6 candidate genes were selected for the current study: *DRD2* TaqI_A and -141C; *DRD3* Ser9Gly; *HTR2A*: 102-T/C and His452Tyr; *HTR2C*: Cys23Ser; *COMT*: Val158Met; *MTHFR*: 677-C/T. These polymorphisms were chosen a priori based on findings in other association studies and determined by Sequenom (Hamburg, Germany) using the Sequenom MassARRAY iPLEX platform at the facilities of the manufacturer. Quality check for genotyping was performed in the overall GROUP study, which encompassed exclusion of polymorphisms and individuals based on missingness and based on departure from Hardy–Weinberg equilibrium in a sample of 398 controls without a psychotic disorder.

2.3. Phenotyping

All patients were evaluated by their attending psychiatrist with the Clinical Global Impression - Improvement (CGI-I) scale at one point in time. This instrument was used to score the change in positive symptoms since the start of the current antipsychotic medication on a seven point scale (1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse). Response was dichotomized for some of the analyses: improvement was defined as a CGI-I score of very much improved or much improved. Attending psychiatrists were blinded to patient's genotype. Other clinical variables that were measured in this study were DSM-IV diagnosis, duration of illness, and antipsychotic medication and dose. Haloperidol dose equivalents were subsequently calculated using power formulas as outlined by [Andreassen et al. \(2010\)](#). To assess DSM-IV diagnosis one of the two structured diagnostic instruments was used: the Comprehensive Assessment of Symptoms and History (CASH ([Andreassen et al., 1992](#))) or the SCAN Schedules for Clinical Assessment for Neuropsychiatry (SCAN 2.1 ([Wing et al., 1990](#))). All raters were trained psychologist or psychiatrist, with extensive clinical experience. They had completed training in the CASH or SCAN. Diagnostic consensus was achieved in the presence of an independent psychiatrist. Psychiatric diagnosis was established according to the criteria of DSM-IV. Haloperidol dose equivalents were subsequently calculated using power formulas as outlined by [Andreassen et al. \(2010\)](#).

2.4. Statistical analysis

Age, duration of illness and haloperidol dose equivalents were compared between patients with and without response and were tested for statistical significance using a Mann–Whitney test or *t*-test when appropriate. We compared response between the most frequently prescribed antipsychotics and between diagnoses and tested differences for statistical significance using the χ^2 test. Ordinal regression ([Scott et al., 1997](#)), with the logit link function, was used to quantify the association between the highly skewed CGI-I score on positive symptoms and polymorphisms, while adjusting for age and gender. Sequential low prevalent outcome groups were pooled to fulfill the assumptions of ordinal regression, i.e. high enough cell counts in each genotype/outcome group (minimum of 1). The null hypothesis of parallel lines

was tested for each polymorphism using χ^2 tests. We considered initially an additive model with the number of minor alleles as independent variable for all polymorphisms. When genotype/outcome group cell counts were too low, a dominant model for the polymorphism was considered. Polymorphisms positioned on the X-chromosome were tested in a dominant model only. All statistical analyses were performed using SPSS 16.0 for Windows. Since all nine polymorphisms were based on earlier positive association studies in Caucasian patients, we refrained from adjusting for the multiple testing. The significance level of this study was set at 0.05, two-sided. Replication was established when the effect was in the same direction as in the original study and statistically significant.

3. Results

Descriptive statistics of our study sample are presented in [Table 1](#) according to response on positive symptoms. Patients with response had a two years higher age (Mann Whitney P value 0.031) and a two months longer treatment period of the current antipsychotic (Mann Whitney P value 0.039) than patients without response. Haloperidol equivalents, duration of illness, DSM-IV diagnoses and type of antipsychotic were not significantly different between response groups.

All polymorphisms were validated and had a missing genotype rate below 10% in the total sample. No polymorphism deviated from Hardy–Weinberg equilibrium. The allele and genotype frequencies are shown in [Table 2](#). Due to the low prevalence of scores 4, 5, 6 and 7 on the CGI-I, we used three ordinal groups of response: a CGI-I score of 1, 2, and 3 or higher. Rs6314 and rs1799732 showed too low cell counts when tested additive, and were subsequently tested dominantly. The null hypothesis of parallel lines was not rejected for any of the polymorphisms tested.

In [Table 3](#) the associations with response are depicted. Two of the nine polymorphisms showed a significant association with response on positive symptoms. The Gly (C) allele of Ser9Gly of the *DRD3* gene was associated with more improvement on positive symptoms (P value 0.034). The T-allele of 677-C/T of the *MTHFR* gene also showed more improvement (P value 0.019). Both results were in the same direction as the previous association studies reporting on these polymorphisms ([Staddon et al., 2002](#); [Szekeres et al., 2004](#); [Scharfetter et al., 1999](#); [Joober et al., 2000a](#)). The Gly-allele and T-allele showed odds ratios of 1.39 (95% CI 1.03–1.90) and 1.45 (95% CI 1.06–1.98) for being in a better response category, respectively.

4. Discussion

In this study we aimed to replicate previously reported significant findings from candidate gene studies on positive symptoms improvement in patients with psychotic disorders treated with antipsychotics. Of the nine tested polymorphisms two were tested significantly: Ser9Gly of the *DRD3* gene and 677-C/T of the *MTHFR* gene.

Previous positive association studies with Ser9Gly of *DRD3* in Caucasian patients were performed in prospective studies with patients using clozapine ([Scharfetter et al., 1999](#)), olanzapine ([Staddon et al., 2002](#)), and several SGA ([Szekeres et al., 2004](#)). In all three studies the Gly allele was associated with better response. All three studies used different symptom scales and treatment duration varied between 12 weeks and 6 months. Three other studies (two clozapine and one FGA) with Caucasian patients showed no significant association

Table 1 Descriptive statistics of 329 Caucasian patients using antipsychotics, stratified by improvement on positive symptoms.

| | Improvement (n=247) | No improvement (n=82) | P-value |
|--|---------------------|-----------------------|---------|
| Age (years), median (range) | 27 (16–47) | 25 (16–42) | 0.031 |
| Gender (male) | 197 (80%) | 63 (77%) | 0.52 |
| Duration of illness (years), median (range) | 3.4 (0.2–21.4) | 3.2 (0.2–12.0) | 0.99 |
| Duration of current treatment (months), median (range) | 4 (1–60) | 6 (1–110) | 0.039 |
| Current dose (haloperidol equivalents ^a), median (range) | 4.8 (0.6–18.2) | 6.6 (0.6–21.0) | 0.33 |
| DSM-IV diagnosis | | | 0.45 |
| Schizophrenia | 163 (66%) | 57 (70%) | |
| Schizo-affective disorder | 37 (15%) | 9 (11%) | |
| Schizophreniform disorder | 6 (2%) | 3 (4%) | |
| Psychotic disorder NOS | 28 (11%) | 9 (11%) | |
| Delusional disorder | 6 (2%) | 4 (5%) | |
| Other | 7 (3%) | 0 (0%) | |
| Antipsychotic | | | 0.24 |
| Risperidone | 55 (22%) | 20 (24%) | |
| Olanzapine | 68 (28%) | 12 (15%) | |
| Quetiapine | 14 (6%) | 4 (5%) | |
| Clozapine | 22 (9%) | 8 (10%) | |
| Haloperidol | 19 (8%) | 5 (6%) | |
| Aripiprazole | 2 (1%) | 3 (4%) | |
| Other | 16 (7%) | 6 (7%) | |
| Multiple antipsychotics | 25 (10%) | 12 (15%) | |
| Missing | 26 (11%) | 12 (15%) | |

^a Calculated as outlined by [Andreasen et al. \(2010\)](#).

(Joober et al., 2000b; Malhotra et al., 1998; Shaikh et al., 1996). In vitro studies indicate that the Gly variant is associated with higher dopamine binding affinity (Lundstrom and Turpin, 1996). However, the biological function is hard to interpret since the Gly variant was mostly associated with poor response in Chinese populations (Reynolds et al., 2005; Lane et al., 2005). This different direction of association with response may be explained by a linkage disequilibrium status with another functional polymorphism.

Only one study has been performed regarding 677-C/T of *MTHFR* and antipsychotic response (Joober et al., 2000a). The T allele was found more often in responders compared to non-responders, all having FGA. The 677-C/T polymorphism

is functional (Frosst et al., 1995) and is possibly associated with risk of schizophrenia itself (Shi et al., 2008; Allen et al., 2008). *MTHFR* is required for the synthesis of 5-methyltetrahydrofolate, the primary circulatory form of folate and the carbon donor for homocysteine remethylation to methionine. Homozygous individuals (TT) have around one third of the expected *MTHFR* enzyme activity, and heterozygotes (CT) have around two third activity, compared to the most common genotype CC (Frosst et al., 1995). Some patients with homocysteinuria, an inborn error of metabolism that can be caused by rare and severe mutations in the *MTHFR* gene, have exhibited schizophrenia-like symptoms (Freeman et al., 1975). Furthermore, high levels of homocysteine have been

Table 2 Frequencies of alleles and genotypes of polymorphisms in 329 Caucasian patients with a non-affective psychotic disorder.

| Gene | rs-id | Chromosome position | Variant name | Alleles ^a | MAF ^b | Genotypes | | |
|-------|-----------|---------------------|--------------|----------------------|------------------|-----------|-----------|-----------------------|
| | | | | | | 11 | 12 | 22 |
| DRD2 | rs1800497 | Chr11:113270827 | TaqI_A | C/T | 0.17 | 228 (69%) | 89 (27%) | 12 (4%) |
| | rs1799732 | Chr11:113346252 | -141C | C/Del | 0.11 | 262 (80%) | 60 (18%) | 5 (2%) |
| DRD3 | rs6280 | Chr3:113890814 | Ser9Gly | T/C | 0.32 | 150 (46%) | 139 (43%) | 36 (11%) |
| HTR2A | rs6314 | Chr13:47409033 | His452Tyr | C/T | 0.1 | 255 (80%) | 59 (19%) | 3 (1%) |
| | rs6311 | Chr13:47471477 | 102-T/C | C/T | 0.45 | 92 (28%) | 177(54%) | 59 (18%) |
| HTR2C | rs3813929 | X:113818519 | -759C_T | C/T | 0.18 | 244 (83%) | – | 49 (17%) ^c |
| | rs6318 | X:113965734 | Cys23Ser | G/C | 0.16 | 249 (84%) | – | 48 (16%) ^c |
| COMT | rs4680 | Chr22:19951270 | Val158Met | A/G | 0.46 | 91 (28%) | 169 (52%) | 68 (21%) |
| MTHFR | rs1801133 | Chr1:11856378 | 677-C/T | C/T | 0.32 | 153 (47%) | 141 (43%) | 35 (11%) |

^a Major allele given first.

^b MAF = minor allele frequency.

^c Carriers of variant allele, polymorphism positioned on X-chromosome.

Table 3 Results of association analyses between polymorphisms and clinical improvement on positive symptoms in 329 Caucasian patients with a non-affective psychotic disorder.

| Gene | rs-id | Variant name | Alleles ^b | Ordinal regression ^a | | P-value |
|--------------------|-----------|--------------|----------------------|---------------------------------|-------------|--------------|
| | | | | Beta | Odds ratio | |
| DRD2 | rs1800497 | TaqI_A | C/T | -0.24 | 0.79 | 0.21 |
| | rs1799732 | -141C | C/Del | -0.36 | 0.70 | 0.17 |
| DRD3 | rs6280 | Ser9Gly | T/C | -0.33 | 0.72 | 0.034 |
| HTR2A | rs6314 | His452Tyr | C/T | -0.17 | 0.84 | 0.53 |
| | rs6311 | T102C | C/T | 0.10 | 1.11 | 0.53 |
| HTR2C ^c | rs3813929 | -759C_T | C/T | 0.08 | 1.08 | 0.79 |
| | rs6318 | Cys23Ser | G/C | -0.47 | 0.63 | 0.13 |
| COMT | rs4680 | Val158Met | A/G | 0.08 | 1.08 | 0.62 |
| MTHFR | rs1801133 | 677-C/T | C/T | -0.37 | 0.69 | 0.019 |

^a Ordinal regression analysis with CGI-I improvement as dependent variable, and the number of minor alleles (0, 1 or 2) of the polymorphism as independent variable (additive model), corrected for age and gender. A negative beta or odds ratio < 1 means more improvement (lower CGI score) per extra minor allele. Significant results ($p < 0.05$) are shown in bold.

^b Major allele given first.

^c Polymorphisms tested in a dominant model.

observed in schizophrenia patients (Regland et al., 1995). Several reports link a high plasma level of homocysteine to various neurological conditions also, such as pregnancies complicated by neural tube defects (Bakker and Brandjes, 1997) and migraine (Oterino et al., 2010). Together with the association we replicated, this points out that MTHFR may be involved in the interaction with antipsychotic medication.

In this study we did not replicate seven of the previously associated polymorphisms with response on positive symptoms. When a more conservative correction for multiple testing was applied, such as Bonferroni, even the two replications would not be significant. An important question regards the explanation of our findings. A likely explanation for the variation in results from pharmacogenetic studies is the heterogeneity in the definition and characterization of the phenotype as well as in the characterization of the genetic variability. This concerns the present study as well. An important difference of our study from other studies is the time between start of the medication and assessment of improvement. The time of assessment is variable in our study, because we measured CGI-I cross-sectionally in our cohort. However, since most patients show response in the first month after the start of an antipsychotic (Derks et al., 2010) we consider our method valid for pharmacogenetic purposes. We have a relatively big group of patients showing improvement, what can be expected when response is cross-sectionally measured. Patients who do not respond well are less likely to continue an antipsychotic and will eventually switch to another antipsychotic. This might have underestimated the results, because we have a smaller range of response outcome. In addition, due to the cross-sectional nature of our study we had to use a relatively generic measure, in this case the CGI-I, to assess response to antipsychotics. This approach might be responsible for a relatively imprecise measurement of the true response. To perform a true replication study, all methodologies and patient characteristics should be identical. This is however not possible when testing different polymorphisms at once, all tested before in different studies with different approaches. Another difference between pharmacogenetic studies on antipsychotics (including ours) is the inclusion of all antipsychotics

as opposed to focusing on a single antipsychotic. Different drug types, treatment duration and response assessment methods may significantly alter study results (Arranz et al., 2000b). We believe that this is a fairly homogeneous group of patients, all with a non-affective psychotic disorder. However, it might very well be possible that pharmacogenetic associations still differ between the diagnoses we included. Of course publication bias might be an important contributing factor as well, i.e. positive results have a better chance of being published than negative results. A combination of above mentioned aspects is probably the reason why most pharmacogenetic association results regarding response on antipsychotics are conflicting: positive associations are often not replicated. Apart from the limitations of the cross-sectional design we used, our study has also several strengths. Compared to most other candidate studies we have a relatively large sample size of more than 300 patients using antipsychotics. Our study does not suffer from heterogeneity with regard to ethnicity as we have a homogeneous group of Caucasian patients of Northern European ancestry.

In conclusion, two of the previously reported associations between polymorphisms and treatment response were replicated in the present study. Heterogeneity in patient samples and outcome variables as well as publication bias may all play a role in lack of replication, found in our study, as in others. The direction of the associations presented here in *DRD3* (Ser9Gly) and *MTHFR* (677-C/T) is in line with previous association studies in Caucasian patients. These polymorphisms may be of clinical value if their added value to other clinical predictors of response can be demonstrated in future research.

Role of the funding source

The infrastructure for the GROUP study is funded by the Geestkracht program of the Dutch Health Research Council (ZON-MW, grant number 10-000-1002) and matching funds from participating universities and Mental Health Care Organizations (Site Amsterdam: Academic Psychiatric Center AMC, Ingeest, Arkin, Dijk en Duin, Rivierduinen, Erasmus MC, GGZ Noord Holland Noord; Site Utrecht: University Medical Centre Utrecht, Altrecht, Symfora, Meerkanten, Riagg Amersfoort, Delta;

Site Groningen: University Medical Center Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGZ Yulius and Parnassia Bavo Group; Site Maastricht: Maastricht University Medical Center, GGZ Eindhoven, GGZ Midden-Brabant, GGZ Oost-Brabant, GGZ Noord-Midden Limburg, Mondriaan Zorggroep, Prins Clauscentrum Sittard, RIAGG Roermond, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Zieken Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem).

ZonMw – or any of the Mental Health Care organizations – had no further role in the study design; in the analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Contributors

All authors designed the study. The GROUP investigators wrote the study protocol. Author Vehof managed the literature searches (together with GROUP investigators and Al Hadithy) and statistical analyses (together with Burger, Snieder and Alizadeh). All authors contributed to and have approved the final manuscript.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgments

For their willingness to cooperate, we thank the patients, their family-members and staff of the participating Mental Health Care Organizations (Site Amsterdam: Academic Psychiatric Center AMC, Ingeest, Arkin, Dijk en Duin, Rivierduinen, Erasmus MC, GGZ Noord Holland Noord; Site Utrecht: University Medical Centre Utrecht, Altrecht, Symfora, Meerkanten, Riagg Amersfoort, Delta; Site Groningen: University Medical Center Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGZ Yulius and Parnassia Bavo Group; Site Maastricht: Maastricht University Medical Center, GGZ Eindhoven, GGZ Midden-Brabant, GGZ Oost-Brabant, GGZ Noord-Midden Limburg, Mondriaan Zorggroep, Prins Clauscentrum Sittard, RIAGG Roermond, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Zieken Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem).

References

- Allen, N.C., Bagade, S., McQueen, M.B., Ioannidis, J.P., Kavvoura, F.K., Khoury, M.J., Tanzi, R.E., Bertram, L., 2008. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. *Nat. Genet.* 40 (7), 827–834.
- Andreasen, N.C., Flaum, M., Arndt, S., 1992. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. *Arch. Gen. Psychiatry* 49 (8), 615–623.
- Andreasen, N.C., Pressler, M., Nopoulos, P., Miller, D., Ho, B.C., 2010. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. *Biol. Psychiatry* 67 (3), 255–262.
- Anttila, S., Illi, A., Kampman, O., Mattila, K.M., Lehtimäki, T., Leinonen, E., 2004. Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. *Pharmacogenetics* 14 (5), 303–307.
- Arranz, M., Collier, D., Sodhi, M., Ball, D., Roberts, G., Price, J., Sham, P., Kerwin, R., 1995. Association between clozapine response and allelic variation in 5-HT_{2A} receptor gene. *Lancet* 346 (8970), 281–282.
- Arranz, M.J., Collier, D.A., Munro, J., Sham, P., Kirov, G., Sodhi, M., Roberts, G., Price, J., Kerwin, R.W., 1996. Analysis of a structural polymorphism in the 5-HT_{2A} receptor and clinical response to clozapine. *Neurosci. Lett.* 217 (2–3), 177–178.
- Arranz, M.J., Munro, J., Owen, M.J., Spurlock, G., Sham, P.C., Zhao, J., Kirov, G., Collier, D.A., Kerwin, R.W., 1998a. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT_{2A} receptor gene and response to clozapine. *Mol. Psychiatry* 3 (1), 61–66.
- Arranz, M.J., Munro, J., Sham, P., Kirov, G., Murray, R.M., Collier, D.A., Kerwin, R.W., 1998b. Meta-analysis of studies on genetic variation in 5-HT_{2A} receptors and clozapine response. *Schizophr. Res.* 32 (2), 93–99.
- Arranz, M.J., Munro, J., Birkett, J., Bolonna, A., Mancama, D., Sodhi, M., Lesch, K.P., Meyer, J.F., Sham, P., Collier, D.A., Murray, R.M., Kerwin, R.W., 2000a. Pharmacogenetic prediction of clozapine response. *Lancet* 355 (9215), 1615–1616.
- Arranz, M.J., Munro, J., Osborne, S., Collier, D., Kerwin, R.W., 2000b. Difficulties in replication of results. *Lancet* 356 (9238), 1359–1360.
- Bakker, R.C., Brandjes, D.P., 1997. Hyperhomocysteinaemia and associated disease. *Pharm. World Sci.* 19 (3), 126–132.
- Bertolino, A., Caforio, G., Blasi, G., De Candia, M., Latorre, V., Petruzzella, V., Altamura, M., Nappi, G., Papa, S., Callicott, J.H., Mattay, V.S., Bellomo, A., Scarabino, T., Weinberger, D.R., Nardini, M., 2004. Interaction of COMT (Val108/158)Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. *Am. J. Psychiatry* 161 (10), 1798–1805.
- Derks, E.M., Fleischhacker, W.W., Boter, H., Peuskens, J., Kahn, R.S., EUFEST Study Group, 2010. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? *J. Clin. Psychopharmacol.* vol. 30 (no. 2), 176–180.
- Freeman, J.M., Finkelstein, J.D., Mudd, S.H., 1975. Folate-responsive homocystinuria and “schizophrenia”. A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity. *N. Engl. J. Med.* 292 (10), 491–496.
- Frosst, P., Blom, H.J., Milos, R., Goyette, P., Sheppard, C.A., Matthews, R.G., Boers, G.J., den Heijer, M., Kluijtmans, L.A., van den Heuvel, L.P., 1995. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat. Genet.* 10 (1), 111–113.
- Hazelwood, L.A., Sanders-Bush, E., 2004. His452Tyr polymorphism in the human 5-HT_{2A} receptor destabilizes the signaling conformation. *Mol. Pharmacol.* 66 (5), 1293–1300.
- Hwang, R., Shinkai, T., De Luca, V., Muller, D.J., Ni, X., Macchiardi, F., Potkin, S., Lieberman, J.A., Meltzer, H.Y., Kennedy, J.L., 2005. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. *Psychopharmacology* 181 (1), 179–187.
- Jonsson, E., Nothen, M.M., Bunzel, R., Propping, P., Sedvall, G., 1996. 5HT 2a receptor T102C polymorphism and schizophrenia. *Lancet* 347 (9018), 1831.
- Jonsson, E.G., Nothen, M.M., Grunhage, F., Farde, L., Nakashima, Y., Propping, P., Sedvall, G.C., 1999. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. *Mol. Psychiatry* 4 (3), 290–296.
- Joober, R., Benkelfat, C., Brisebois, K., Toulouse, A., Turecki, G., Lal, S., Bloom, D., Labelle, A., Lalonde, P., Fortin, D., Alda, M., Palmour, R., Rouleau, G.A., 1999. T102C polymorphism in the 5HT_{2A} gene and schizophrenia: relation to phenotype and drug response variability. *J. Psychiatry Neurosci.* 24 (2), 141–146.
- Joober, R., Benkelfat, C., Lal, S., Bloom, D., Labelle, A., Lalonde, P., Turecki, G., Rozen, R., Rouleau, G.A., 2000a. Association

- between the methylenetetrahydrofolate reductase 677C→T missense mutation and schizophrenia. *Mol. Psychiatry* 5 (3), 323–326.
- Joob, R., Toulouse, A., Benkelfat, C., Lal, S., Bloom, D., Labelle, A., Lalonde, P., Turecki, G., Rouleau, G.A., 2000b. DRD3 and DAT1 genes in schizophrenia: an association study. *J. Psychiatr. Res.* 34 (4–5), 285–291.
- Laakso, A., Pohjalainen, T., Bergman, J., Kajander, J., Haaparanta, M., Solin, O., Syvalahti, E., Hietala, J., 2005. The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects. *Pharmacogenet. Genomics* 15 (6), 387–391.
- Lacro, J.P., Dunn, L.B., Dolder, C.R., Leckband, S.G., Jeste, D.V., 2002. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. *J. Clin. Psychiatry* 63 (10), 892–909.
- Lane, H.Y., Hsu, S.K., Liu, Y.C., Chang, Y.C., Huang, C.H., Chang, W.H., 2005. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. *J. Clin. Psychopharmacol.* 25 (1), 6–11.
- Lencz, T., Robinson, D.G., Xu, K., Ekholm, J., Sevy, S., Gunduz-Bruce, H., Woerner, M.G., Kane, J.M., Goldman, D., Malhotra, A.K., 2006. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. *Am. J. Psychiatry* 163 (3), 529–531.
- Lieberman, J.A., Maiman, R.B., Duncan, G., Sikich, L., Chakos, M., Nichols, D.E., Kraus, J.E., 1998. Serotonergic basis of antipsychotic drug effects in schizophrenia. *Biol. Psychiatry* 44 (11), 1099–1117.
- Lundstrom, K., Turpin, M.P., 1996. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. *Biochem. Biophys. Res. Commun.* 225 (3), 1068–1072.
- Malhotra, A.K., Goldman, D., Ozaki, N., Breier, A., Buchanan, R., Pickar, D., 1996. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. *Am. J. Psychiatry* 153 (8), 1092–1094.
- Malhotra, A.K., Goldman, D., Buchanan, R.W., Rooney, W., Clifton, A., Kosmidis, M.H., Breier, A., Pickar, D., 1998. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. *Mol. Psychiatry* 3 (1), 72–75.
- Masellis, M., Paterson, A.D., Badri, F., Lieberman, J.A., Meltzer, H.Y., Cavazzoni, P., Kennedy, J.L., 1995. Genetic variation of 5-HT2A receptor and response to clozapine. *Lancet* 346 (8982), 1108.
- Masellis, M., Basile, V., Meltzer, H.Y., Lieberman, J.A., Sevy, S., Macciardi, F.M., Cola, P., Howard, A., Badri, F., Nothen, M.M., Kalow, W., Kennedy, J.L., 1998. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. *Neuropsychopharmacology* 19 (2), 123–132.
- Oterino, A., Toriello, M., Valle, N., Castillo, J., Alonso-Arranz, A., Bravo, Y., Ruiz-Alegria, C., Quintela, E., Pascual, J., 2010. The relationship between homocysteine and genes of folate-related enzymes in migraine patients. *Headache* 50 (1), 99–168.
- Parsons, M.J., D'Souza, U.M., Arranz, M.J., Kerwin, R.W., Makoff, A.J., 2004. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. *Biol. Psychiatry* 56 (6), 406–410.
- Pohjalainen, T., Rinne, J.O., Nagren, K., Lehtikainen, P., Anttila, K., Syvalahti, E.K., Hietala, J., 1998. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. *Mol. Psychiatry* 3 (3), 256–260.
- Regland, B., Johansson, B.V., Grenfeldt, B., Hjelmgren, L.T., Medhus, M., 1995. Homocysteinemia is a common feature of schizophrenia. *J. Neural Transm. Gen. Sect.* 100 (2), 165–169.
- Reynolds, G.P., Yao, Z., Zhang, X., Sun, J., Zhang, Z., 2005. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. *Eur. Neuropsychopharmacol.* 15 (2), 143–151.
- Schäfer, M., Rujescu, D., Giegling, I., Guntermann, A., Erfurth, A., Bondy, B., Möller, H.J., 2001. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. *Am. J. Psychiatry* 158 (5), 802–804.
- Scharfetter, J., Chaudhry, H.R., Hornik, K., Fuchs, K., Sieghart, W., Kasper, S., Aschauer, H.N., 1999. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. *Eur. Neuropsychopharmacol.* 10 (1), 17–20.
- Schwartz, J.C., Diaz, J., Pilon, C., Sokoloff, P., 2000. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. *Brain Res. Brain Res. Rev.* 31 (2–3), 277–287.
- Scott, S.C., Goldberg, M.S., Mayo, N.E., 1997. Statistical assessment of ordinal outcomes in comparative studies. *J. Clin. Epidemiol.* 50 (1), 45–55.
- Shaikh, S., Collier, D.A., Sham, P.C., Ball, D., Aitchison, K., Vallada, H., Smith, I., Gill, M., Kerwin, R.W., 1996. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. *Hum. Genet.* 97 (6), 714–719.
- Shi, J., Gershon, E.S., Liu, C., 2008. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. *Schizophr. Res.* 104 (1–3), 96–107.
- Sodhi, M.S., Arranz, M.J., Curtis, D., Ball, D.M., Sham, P., Roberts, G.W., Price, J., Collier, D.A., Kerwin, R.W., 1995. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. *Neuroreport* 7 (1), 169–172.
- Staddon, S., Arranz, M.J., Mancama, D., Mata, I., Kerwin, R.W., 2002. Clinical applications of pharmacogenetics in psychiatry. *Psychopharmacology* 162 (1), 18–23.
- Szekeres, G., Keri, S., Juhasz, Z., Rimanoczy, A., Szendi, I., Czimmer, C., Janka, Z., 2004. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 124B (1), 1–5.
- Tsuang, M.T., Lyons, M.J., Faraone, S.V., 1990. Heterogeneity of schizophrenia conceptual models and analytic strategies. *Br. J. Psychiatry* 156, 17–26.
- Wing, J.K., Babor, T., Brugha, T., Burke, J., Cooper, J.E., Giel, R., Jablenski, A., Regier, D., Sartorius, N., 1990. SCAN. Schedules for clinical assessment in neuropsychiatry. *Arch. Gen. Psychiatry* 47 (6), 589–593.